-
AVXL Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Anavex Life Sciences (AVXL)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 120.78 mm | 120.78 mm | 120.78 mm | 120.78 mm | 120.78 mm | 120.78 mm |
Cash burn (monthly) | 3.80 mm | 1.92 mm | 4.53 mm | 4.60 mm | 4.04 mm | 2.97 mm |
Cash used (since last report) | 8.75 mm | 4.41 mm | 10.42 mm | 10.57 mm | 9.29 mm | 6.82 mm |
Cash remaining | 112.03 mm | 116.37 mm | 110.36 mm | 110.20 mm | 111.49 mm | 113.95 mm |
Runway (months of cash) | 29.5 | 60.7 | 24.4 | 24.0 | 27.6 | 38.4 |
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 52 |
Closed positions | 23 |
Increased positions | 49 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 308.66 bn |
Total shares | 29.53 mm |
Total puts | 770.70 k |
Total calls | 893.70 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 6.55 mm | $70.37 bn |
Vanguard | 4.68 mm | $50.27 bn |
STT State Street | 2.41 mm | $25.90 bn |
Geode Capital Management | 1.87 mm | $20.14 bn |
Susquehanna International | 1.13 mm | $12.19 bn |
Nwam | 913.05 k | $9.81 bn |
MS Morgan Stanley | 904.16 k | $9.71 bn |
Two Sigma Investments | 776.90 k | $8.34 bn |
NTRS Northern Trust | 706.90 k | $7.59 bn |
Charles Schwab Investment Management | 677.22 k | $7.27 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jan 25 | Sandra Boenisch | Stock Option Common Stock | Grant | Acquire A | No | No | 8.57 | 12,500 | 107.13 k | 12,500 |
15 Jan 25 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 8.57 | 125,000 | 1.07 mm | 125,000 |
15 Jan 25 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 7.54 | 166,666 | 1.26 mm | 166,000 |
19 Dec 24 | Sandra Boenisch | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 12,500 | 67.00 k | 12,500 |
19 Dec 24 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 125,000 | 670.00 k | 125,000 |
19 Nov 24 | Sandra Boenisch | Stock Option Common Stock | Grant | Acquire A | No | No | 10.09 | 10,000 | 100.90 k | 20,000 |